IND Update: First Clinical-Stage CRISPR Therapy for HIV

This week, we look at a CRISPR-based therapy for HIV that has just passed the IND approval stage, and will soon be tested in a Phase 1/2 clinical trial.

By: Karen O'Hanlon Cohrt - Sep. 22, 2021

Excision BioTherapeutics, a private company that develops gene-editing anti-viral therapies announced last week that the FDA had cleared its HIV candidate EBT-101 for clinical trial initiation in the US. This is the first time that the FDA has given IND approval to a CRISPR-based therapy for HIV.

The company is developing EBT-101 as a potential cure for chronic HIV infection, and the trial will specifically assess the safety, tolerability and efficacy of the new drug candidate in individuals living with HIV type 1, which is the subtype present in about 95 % of HIV cases worldwide.

EBT-101 is developed as an in vivo CRISPR therapy

HIV is an RNA virus, and when it first infects an individual, its RNA is reverse-transcribed into DNA by virally-encoded reverse transcriptase and RNase H enzymes that convert the viral RNA to double-stranded DNA (dsDNA) and degrade any remaining viral RNA, respectively. The resulting dsDNA is integrated into the host genome and this is referred to as proviral RNA.

EBT-101 is designed to excise HIV proviral DNA using CRISPR-Cas9 and two guide RNAs (gRNAs). The CRISPR cargo is delivered to cells as a one-time treatment via an adeno-associated virus (AAV). The two gRNAs target three sites within the HIV genome (Figure 1), thereby cutting out large portions of the HIV genome and minimising potential viral escape.

Figure 1. Excision’s CRISPR-based anti-viral approach: Dual gRNAs excise large sections of viral...
Figure 1. Excision’s CRISPR-based anti-viral approach: Dual gRNAs excise large sections of viral DNA, eliminating viral escape and reproduction. The result is curative. Image source: www.excision.bio.

Pre-clinical studies demonstrate curative potential

Previously reported pre-clinical studies carried out in the lab of Kamel Khalili at Temple University in Philadelphia, which is associated with Excision BioTherapeutics, demonstrated that EBT-101 could remove HIV proviral DNA from multiple cell lines as well as the genomes of transgenic mice. This was the first demonstration of a functional cure for HIV in animals, and the work was carried out in collaboration with Dr. Howard Gendelman's group at the University of Nebraska Medical Center.

Subsequent proof-of-concept studies shed similar findings in rhesus macaque monkeys infected with the related simian immunodeficiency virus (SIV), where a single systemic treatment with AAV9-delivered Cas9 and dual gRNAs could remove proviral DNA from the genomes of blood cells and other tissues known to be viral reservoirs.

EBT-101 is Excision’s lead programme, and the company’s proprietary viral excision technology was developed at Kamel Khalili's lab at Temple University and Jennifer Doudna’s lab at UC Berkeley.

We will provide updates on the EBT-101 clinical trial as they become available.

For a complete overview of CRISPR IND approvals and ongoing gene-editing clinical trials, check out CRISPR Medicine News' Clinical Trials Database.

Tags

HashtagArticleHashtagNewsHashtagIn-vivoHashtagAdeno-associated virus (AAV)HashtagHuman Immunodeficiency Virus Infection, HIVHashtagViral diseaseHashtagBlood diseaseHashtagCRISPR-CasHashtagCas9HashtagFDAHashtagExcision BioTherapeuticsHashtagIND - Investigational New Drug

CLINICAL TRIALS
Acute Myeloid Leukemia, AML, (NCT05066165)
Sponsors:
Intellia Therapeutics
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
CAR T for CD19+ hematological cancers, (NCT05037669)
Sponsors:
University of Pennsylvania
Indicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine